Colinz Laboratories Ltd (COLINZ) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Colinz Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
The Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review ....
Financial Result · 29 Oct 2026, 11:11 pm
Colinz Laboratories Reports Q2 FY27 Results with Flat Operational Profitability Colinz Laboratories posted revenue from operations of ₹155.00 lakhs for the quarter ended 30th Sep'26, rising 11.67% YoY from ₹138.80 lakhs and 24.91% QoQ from ₹124.09 lakhs. Total income reached ₹168.91 lakhs against total expenses of ₹150.26 lakhs. Profit before tax stood flat YoY at ₹18.65 lakhs, while net profit declined 9.96% YoY to ₹12.65 lakhs compared to ₹14.05 lakhs in the previous year quarter, generating an EPS of ₹0.50. For H1 ended 30th Sep'26, operational revenue totaled ₹279.09 lakhs.
We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 29th October, 2026 has, inter alia considered and approved Unaudited Financial Results ....
Outcome · 29 Oct 2026, 11:03 pm
Colinz Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 155 (+11.7% YoY | +24.9% QoQ) ■ EBITDA: 8.2 (+3.1% YoY | +30.8% QoQ) ■ EBITDA Margin (%): 5.3 (-44 bps YoY | +24 bps QoQ) ■ PAT: 12.7 (-10.0% YoY | -94.7% QoQ) ■ EPS (INR): 0.50 (-10.7% YoY | -94.8% QoQ)
Colinz Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve We wish to inform you that ....
Intimation · 29 Oct 2026, 5:30 am
Colinz Laboratories Schedules Board Meeting for Q2 FY27 Financial Results Colinz Laboratories Ltd. has scheduled a Board of Directors meeting on 29th Oct'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in the company's equity shares has been closed since 1st Oct'26 and will remain closed until 48 hours after the financial results are communicated to the stock exchange.
Dear Sir, PFA, attached Certificate under Regulation 32 of SEBI(LODR) Regulation,2015 and Statement of Deviation or Variation is NOT applicable to the Company for the Quarter Ended on ....
Rights Issue · 01 Oct 2026, 7:54 pm
Colinz Laboratories Declares Non-Applicability of SEBI Regulation 32 for Q2 FY27 Colinz Laboratories Limited submitted a regulatory filing to the BSE confirming the non-applicability of Regulation 32 of SEBI (LODR) Regulations, 2015, for the quarter ended 30th Sep'26. The company stated that reporting deviations or variations in the use of proceeds is not applicable as it did not raise funds through any public issue, rights issue, preferential issue, or Qualified Institutional Placement (QIP) during the period.
Dear Sir, Pursuant to Regulations23(9) of SEBI (LODR). Regulations,2015, the said Regulation is not applicable to us, Kindly take the Non-Applicability Certificate on records for Quarter ....
Others (Uncategorized) · 01 Oct 2026, 7:48 pm
Colinz Laboratories Declares Non-Applicability of Related Party Transaction Disclosures Colinz Laboratories Limited has informed the BSE that compliance with Regulation 23(9) of SEBI (LODR) Regulations, 2015, regarding Related Party Transaction disclosures, is not applicable to the company for the quarter ended 30th Sep'26. The company is claiming an exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015, which exempts it from the corporate governance provisions specified under Regulations 17 to 27. Consequently, the company will not be submitting related-party disclosures for the quarter.
Please find enclosed herewith the Srutinizers Report for our 40th AGM held on 22-09-2026 issued todted dated 23-09-2026. Kindly take the same on records. For Colinz Labs Ltd Director
Annual General Meeting · 23 Sept 2026, 9:04 pm
DEAR SIR SUMMERY OF OF 40TH AGM HELD ON 22-09-2026 AT 2.30 PM . KINDLY TAKE THE SAME ON RECORDS FOR COLINZ LABORATORIES LTD VIJAYA MANI CHAIRPESRSON OF THE MEETING
Annual General Meeting · 22 Sept 2026, 11:09 pm
Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post Offer Advertisement under Regulation 18(12) of The Securities and Exchange Board of India ....
Others (Uncategorized) · 05 Sept 2026, 1:04 am
Acquirers Conclude Open Offer for Colinz Laboratories Limited Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with PAC Padam Dugar, completed an open offer to acquire up to 6,54,966 equity shares (26.00% voting capital) of Colinz Laboratories Ltd at ₹54 per share. During the tendering period from 7th Aug'26 to 20th Aug'26, only 6 demat shares (negligible percentage) were tendered and accepted, totaling ₹324. Consequently, post-offer shareholding of the acquirers and PAC stands at 12,48,506 equity shares (49.57% voting capital), including agreed acquisitions under the share purchase agreement dated 18th Jun'26.
Dear Sir, Pursuant to Regulation 34(1) and Regulation 30 of SEBI(LODR),Regulations ,2015. Please find the attached our 40th Annual Report for the FY 2025-26. Kindly take the same on ....
Others (Uncategorized) · 20 Aug 2026, 8:56 pm
As required under SEBI (LODR)Regulaions, 2015 and Section 108 Companies Act 2013 Reas with Rule 20 and other Applicable Rules thereunder, we are submitting herewith 40th AGM Notice of our ....
Annual General Meeting · 20 Aug 2026, 8:18 pm
Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Reminder Advertisement dated August 11, 2026 in relation to the open offer of Colinz Laboratories ....
Others (Uncategorized) · 12 Aug 2026, 11:49 pm
Colinz Laboratories: Promoters Announce Open Offer for 26% Stake An open offer has been announced by promoters Annjana, Likhitta, and Antariksh Dugar, along with Padam Dugar (PAC), for Colinz Laboratories Ltd. The offer seeks to acquire up to 654,966 equity shares, representing 26% of the company's voting share capital. The offer price is set at ₹54 per share, cash, for an aggregate consideration of up to ₹3.53 crore. This action is pursuant to SEBI (SAST) Regulations, 2011. Saffron Capital Advisors is the manager to the offer. The reminder advertisement was published on Aug 12, '26.
Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of offer opening public announcement under Regulation 18(7) of the SEBI (SAST) Regulations, 2011, ....
Others (Uncategorized) · 06 Aug 2026, 11:34 pm
Colinz Laboratories Open Offer Announced by Dugar Family Dugar family members, acting in concert, announced a mandatory open offer to acquire up to 654,966 equity shares of Colinz Laboratories Ltd, representing 26% of voting share capital. The cash offer is priced at ₹54 per share, aggregating up to ₹3.54 cr. Saffron Capital Advisors is managing the offer. The offer opening public announcement was published on Aug 06, '26, following the detailed public statement on Aug 05, '26. This action is pursuant to SEBI (SAST) Regulations, 2011, for substantial acquisition of shares.
Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Letter of Offer for the attention of the Public Shareholders of Colinz Laboratories Ltd ("Target ....
Others (Uncategorized) · 31 Jul 2026, 11:33 pm
Acquirers Launch Mandatory Open Offer for 26% of Colinz Laboratories at ₹54/Share Annjana Dugar and family (Acquirers/PAC), represented by Saffron Capital Advisors, have launched a mandatory open offer to acquire up to 654,966 shares (26% stake) of Colinz Laboratories Ltd. at ₹54 per share. The offer, aggregating to ₹3.54 Cr, was triggered by a Share Purchase Agreement to acquire 34.56% of the company for ₹4.35 Cr (at ₹50/share). The acquirers' post-offer shareholding, assuming full acceptance, will rise to 75.56%. The offer period is from 7th Aug'26 to 20th Aug'26.
Please find the attached OUTCOME of the meeting held today dated 30-07-2026 the details of the approved agenda are shown in the OUTCOME.
Financial Result · 30 Jul 2026, 11:20 pm
Colinz Labs Q1FY27 Net Profit Surges on Exceptional Gain from Asset Sale Colinz Laboratories reported a significant net profit increase to ₹240.12 lakhs for Q1FY27, up from ₹11.92 lakhs YoY. This surge was driven by an exceptional gain of ₹276.33 lakhs from the sale of fixed assets. Revenue from operations declined 20.8% YoY to ₹124.09 lakhs. The Board approved the appointment of Mrs. Vijaya Mani as a Promoter & Non-Executive Director and re-appointed Mr. N. K. Menon as Whole-time Director & CEO for one year from 01 Oct'26. Basic EPS stood at ₹9.53.
1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June, 2026 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) ....
Outcome · 30 Jul 2026, 11:12 pm
Colinz Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 124 (-20.8% YoY | -29.0% QoQ) ■ EBITDA: 6.3 (-54.0% YoY | -31.1% QoQ) ■ EBITDA Margin (%): 5.0 (-365 bps YoY | -16 bps QoQ) ■ PAT: 240 (+1914.4% YoY | +1302.6% QoQ) ■ EPS (INR): 9.53 (+1927.7% YoY | +1301.5% QoQ)
Colinz Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve This is to inform the exchange ....
Intimation · 30 Jul 2026, 5:30 am
Colinz Laboratories Board Meeting Scheduled for 30th July to Approve Q1 Results Colinz Laboratories' Board of Directors will meet on 30th Jul'26 to consider and approve the un-audited financial results for the quarter ended 30th Jun'26. The agenda also includes approving the Director's Report for FY26, fixing book closure and record dates, and considering appointments for the Secretarial and Internal Auditors for FY27. The board will also approve the draft notice for the forthcoming Annual General Meeting. The trading window for designated persons will end on the second trading day after this meeting.
Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer ("DLOF") for the attention of the Public Shareholders of Colinz Laboratories ....
Others (Uncategorized) · 04 Jul 2026, 1:53 pm
Dugar Family Announces Open Offer for 26% of Colinz Laboratories Ltd Annjana Dugar, Likhitta Dugar, Antariksh Dugar, and Padam Dugar have proposed a mandatory open offer to acquire up to 654,966 equity shares of Colinz Laboratories Ltd, representing 26% of the voting share capital. The offer price is set at ₹54 per share, aggregating up to ₹3.54 Cr. This follows the acquirers' execution of a Share Purchase Agreement on 18 Jun'26 to acquire an additional 34.56% stake at ₹50 per share. The offer's tendering period is scheduled from 11 Aug'26 to 24 Aug'26.
Dear Sir, Please find the attached Certificate from our PCA towards Non-Applicability of Corporate Governence as required under 15(2) of SEBI LODR, 2015. Kindly take the same on records. For ....
Others (Uncategorized) · 03 Jul 2026, 6:25 pm
Colinz Laboratories Exempt from SEBI Corporate Governance Reporting for Q1FY27 Colinz Laboratories (BSE: 531210) confirmed its exemption from filing the Corporate Governance Report under SEBI's Regulation 27(2) for the quarter ending 30th Jun'26. The exemption is due to its paid-up equity share capital and net worth remaining below the regulatory thresholds of Rs. 10 crore and Rs. 25 crore, respectively. As of 31st Mar'26, the company's paid-up capital was stable at Rs. 2.52 crore, while its net worth increased to Rs. 10.04 crore from Rs. 9.47 crore a year prior.
Dear Sir, Please find the attached Disclosure as required under Regulation 32 of SEBI (LODR), 2015 for the Quarter Ended on june-26. Kindly take the same on records . For Colinz Labs ....
Rights Issue · 03 Jul 2026, 6:19 pm
Colinz Labs Confirms No Fund Utilization Deviation for Q1 FY27 Colinz Laboratories Ltd informed the BSE that Regulation 32 of SEBI (LODR) Regulations, 2015, is not applicable for the quarter ended 30 Jun'26. The company confirmed it had not raised funds through any public issue, rights issue, preferential issue, or QIP. Therefore, a statement of deviation or variation in the use of proceeds is not required for the period.
Please find the attached Disclosure towards NOn-Applicability of Related Party Transactions as per SEBI Regulation 23(9) for LODR, 2015. for the Quarter Ended on June-26. Kindly take ....
Others (Uncategorized) · 03 Jul 2026, 6:14 pm
Colinz Laboratories Claims Exemption from Related Party Transaction Disclosures Colinz Laboratories Limited (BSE: 531210) has declared that the requirement to submit Related Party Transaction (RPT) disclosures under Regulation 23(9) of SEBI (LODR) Regulations, 2015 is not applicable to the company. Citing an exemption under Regulation 15(2)(a), the company will not file RPT disclosures for the quarter ended 30th Jun'26. This exemption also applies to corporate governance provisions specified in Regulations 17 to 27, among others. The notice was filed on 03rd Jul'26.
Dear Sirs, This has reference to the above captioned subject , we are submitting herewith the Discloure under Regulation 30 as amnded from time to time The Completion of our Factory ....
Others (Uncategorized) · 27 Jun 2026, 8:20 pm
Colinz Laboratories Completes Factory Undertaking Sale for Rs. 4 Crore Colinz Laboratories (BSE: 531210) completed the sale of its factory undertaking in Sinnar, Nashik on 18th Jun'26, receiving the final payment tranche. The total consideration for the factory building, machinery, and land was Rs. 4 crore. The buyer is M/s. Hilsun Foods And Drugs Private Limited, an unrelated third party. This asset disposal was an arm's length transaction and falls outside any Scheme of Arrangement. The company received the final consideration on 27th Jun'26, concluding the sale process initiated in Jan'26.
Saffron Capital Advisors Private Limited ("Manager to the Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulation 3(1) and 4 read with Regulations 13(4), ....
Others (Uncategorized) · 27 Jun 2026, 4:53 pm
Open Offer for 26% Stake in Colinz Laboratories by Dugar Family Annjana, Likhitta, and Antariksh Dugar, along with Padam Dugar (PAC), have announced a mandatory open offer to acquire a 26% stake in Colinz Laboratories Ltd. This represents 6,54,966 fully paid-up equity shares. The offer price is set at ₹54 per share, aggregating to a total consideration of ₹3.54 crore. The Detailed Public Statement was published on 25 Jun'26. Saffron Capital Advisors is the manager to the offer. The offer is triggered under SEBI (SAST) Regulations, 2011.
Please the attached disclosure under regularion 30 and 30A of SEBI (LODR) Regulation 2015. towards Sales of Promoter Shares. The details informatiom is attahced in the below attachement. ....
Others (Uncategorized) · 18 Jun 2026, 11:49 pm
Colinz Promoter Sells 34.56% Stake; Triggers Open Offer Promoter Vijaya Mani executed a Share Purchase Agreement on 18th Jun'26 to sell 8,70,500 equity shares, representing a 34.56% stake in Colinz Laboratories, for Rs. 50/- per share. The acquirers are Annjana, Likhitta, and Antraiksh Dugar, who will gain control and management rights. This transaction triggers a mandatory Open Offer to public shareholders under SEBI Takeover Regulations, 2011. Post-closing, the acquirers will be classified as the new promoter group, and the seller will cease to have control over the company.
Saffron Capital Advisors Private Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulations 3(1) and 4 ead with Regulations 13, 14 and 15(1) of ....
Others (Uncategorized) · 18 Jun 2026, 10:43 pm
Colinz Laboratories Open Offer Triggered by Dugar Family Dugar family members, as Acquirers and PAC, launched an open offer on Jun 18, '26, for Colinz Laboratories Ltd (BSE: 531210). This follows a Share Purchase Agreement to acquire 870,500 shares (34.56%) from promoter Vijaya Mani at ₹50/share. The mandatory open offer seeks to acquire up to 654,966 additional shares, representing 26% of voting capital, from public shareholders at ₹54/share. The total offer size is ₹3.54 crore. Post-transaction, the acquirer group's shareholding will increase from 15.01% to a controlling 49.56%.
This has reference to your mail asking clarification on 01-06-2026. Please find our reply and also clarification for significant movment in our share price in this month. Kindly ccept ....
Others (Uncategorized) · 11 Jun 2026, 10:01 pm
Colinz Laboratories Clarifies Significant Share Price Movement In a letter dated 11th Jun'26, Colinz Laboratories responded to a BSE inquiry regarding significant share price movement. The company confirmed it has disclosed all material information in compliance with SEBI regulations. Management stated there is no unpublished price-sensitive information or pending announcement that could explain the stock's recent activity. The company attributes the price movement to market-driven factors, investor perception, and market conditions, clarifying it has no role in the share price behavior.